Exponential Biotherapies, Inc. (EBI) is a highly innovative biopharmaceutical company that specializes in developing a new class of therapeutic agents to address hemodynamic instability in critically ill patients. With a strong presence in both the United States and the Netherlands, EBI operates at the forefront of biopharmaceutical development.

EBI's mission is to tackle the unmet need for solutions to negative health outcomes caused by fluid overload in critical care patients. The company's groundbreaking approach allows them to both treat and prevent organ damage resulting from fluid overload, setting them apart from others in the field. By commercializing small peptides, EBI aims to revolutionize critical care interventions.

Led by a team of experienced professionals, including CEO Dirk-Jan van Suchtelen and CFO Niels Bakker, EBI benefits from a diverse range of expertise. Expert advisors like Mr. Johan Renes and Mr.

Gert Wensvoort bring their strategic guidance and experience in the life sciences and biotech sectors. With the support of an esteemed Scientific Advisory Board, including Prof. Eric Claassen and Prof.

Bob Pinedo, EBI ensures that their projects are fueled by cutting-edge research and innovation. Their Clinical Project Manager, Elke van Wachem, brings extensive experience in managing preclinical and clinical studies, particularly with the product EA-230. Through their dedication and groundbreaking advancements, EBI aims to improve patient outcomes and revolutionize critical care interventions